| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
ArcSight, an HP company, is a leading global provider of security and compliance management solutions that intelligently identify and mitigate cyber threat and risk for businesses and government agencies.
GovPilot is a cloud-based government management platform that streamlines operations and digital services provided by local governments for more than 125 critical processes.
EXsquared is a Austin, TX-based company in the Software and Internet sector.